Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder

Patient Inclusion Criteria: * Men and women aged between 20 and 65 * Diagnosis of generalized anxiety disorder as assessed by Structured Clinical Interview for DSM-IV (SCID-IV) * Depressive symptom scores measured by Hamilton Depression Rating Scale at screening and baseline assessments: \>=8 and \<=16 Healthy Control Subject Inclusion Criteria * Healthy men and women aged between 20 and 65 Exclusion Criteria: * Presence of any major physical or neurological illness (e.g.， head trauma, epilepsy， seizure， stroke， cerebral tumor， multiple sclerosis，cerebrovascular disease， narrow-angle glaucoma， drug hypersensitivity， etc.) * Drug abuse in past 3 months * Contraindications to magnetic resonance imaging (e.g., pacemaker implantation，claustrophobia, etc.) * Diagnosis of any Axis I disorder other than generalized anxiety disorder or presence of symptoms requiring hospitalization * Major depressive episode during past 12 months * Depressive symptom scores measured by Hamilton Depression Rating Scale: \>=17 * Women who are pregnant, breastfeeding, or planning pregnancy * Contraindications to drugs used in the study (e.g., allergy, intolerance, etc.) * Unstable medical illness or severe abnormality in laboratory test at screening assessment * Use of psychoactive medications that may affect brain imaging findings * Intelligence quotient below 80